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is Less sensitive but has a higher specificity and 
PPV than PCR. One possible future scenario is the 
combined use of both tests to design a strategy of 
pre-emptive antifungaL therapy in order to select 
the patients who do not need of early empirical 
treatment. 
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Background: In Leukemic patients IFI are associ- 
ated with severe morbidity and high mortality (30 
to 90%). Moreover, IFI may have a negative impact 
on treatment and outcome of Leukemia. Recent 
progresses in diagnosis and management of IFI may 
have improved outcome. 
Objectives: To evaluate the morbidity and mortaL- 
ity of proven/probabLe IFI in adult non-aLLo-HSCT 
neutropenic patients with acute Leukemia. 
Methods: CLinicaL, radioLogicaL, and Laboratory 
data were prospectively coLLected in consecu- 
tive neutropenic patients with acute Leukemia 
(2002-2005). Antifunga[ prophylaxis was not used 
routinely. IFI were classified as proven, probable, 
or possible (EORTC-BAMSG). Proven/probabLe IFI 
cases were compared to controls (no IFI). 
Results: 157 neutropenic episodes (91 induction 
chemotherapy, 64 consolidation, 2 auto-HSCT) oc- 
curred in 86 patients (73 AML, 13 ALL). Median age 
was 57yr (range 19-77). IFI was proven/probabLe in 
26 cases (14 aspergillosis, 14 candidiasis, including 
2 mixed IFI) and possible in 28. Proven/probabLe IFI 
occurred during induction chemotherapy in 69% of 
cases. At admission neutropenia was present in 
27% of IFI cases. Median days of in-hospitaL neu- 
tropenia were 25 (range 16-71) vs. 20 (range 
7-59), respectively (p<0.05). AntifungaL therapy 
was started after a median of 3 clays (range 0-13) 
after fever onset. Initial antifungaL therapy con- 
sisted of ampho B-deoxychoLate (n= 17), voricona- 
zoLe (n = 5), caspofungin (n = 2), fluconazoLe (n = 2). 
Criteria for proven/probabLe IFI were met a median 
of 12 clays (range 1-51 ) after fever onset. Morbidity 
and mortality in proven/probabLe IFI (n = 26) cases 
versus controls (n = 103, no IFI) were as foLLows: Me- 
dian clays of hospital stay (range): 43 (26-90)* vs 32 
(16-68), P < 0.05 (*4 patients had thoracic surgery). 
Median days between recovery from neutropenia 
and next chemotherapy (range): 15 (11-45) vs 11 
(1-53), P < 0.05. Patients requiring ICU: 4 (15%) vs 
9 (9%), NS. ICU because of IFI: 2 (8%). MortaLity: 
3 (11.5%) vs 2 (2%), NS. MortaLity due to IFI: 1 (4%). 
Conclusions: In adult non-aLLo-HSCT patients with 
acute Leukemia and neutropenia, proven/probabLe 
IFI were associated with moderate morbidity (Low 
rate of ICU admission, minimal delay of initiation 
of next chemotherapy) and tow attributable mor- 
tality (4%) despite prolongation of hospital stay, 
suggesting a trend towards reduced burden of IFI. 
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Background: BLoodstream infections due to Can- 
dida species are becoming increasingly important 
causes of morbidity and mortality in immunocom- 
promised and other severely iLL patients. 
Objective: The aim of this study was to evaluate 
the incidence of nosocomiaL candidemia among 
patients admitted to our hospitaL. Cases included 
patients undergoing most medical and surgical in- 
terventions. 
Causative pathogens, potential predisposing fac- 
tors, treatment, and risk factors for death were 
also evaluated. 
Methods: Demographic information, risk factors, 
therapy and outcome of aLL patients who con- 
tracted candidemia at Saitama Medical School Hos- 
pital from January 2000 to December 2005 were 
identified through the records of the department of 
CLinicaL MicrobioLogy and reviewed retrospectively. 
Cases of candidemia were dated to the first isoLa- 
tion of any Candida spp. from the patient's blood 
culture. 
Results: A total of 104 episodes of Candida 
bloodstream infections occurring in 104 adult pa- 
tients were identified. In this retrospective study, 
the average incidence of candidemia was 0.38 
cases per 10,000 patient-days. The candidemia pa- 
tient population comprised 68 males and 36 fe- 
males, with a mean age of 67 years. Among 
these patients (n=104), the most frequent un- 
derlying diseases/conditions were neopLasia (41%) 
and cardio-vascuLar diseases (36%). Candida al- 
bicans was the most frequently isolated species 
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(52 strains, 49%), foLLowed by C. pampsilosis (26%) 
and C. slabmta (13%). A total of 55 (53%) of 104 
adult patients had received adequate antifunga[ 
treatment, of whom 43 (78%) were treated with 
fluconazoLe and eight (15%) with micafungin; on 
the other hand, 33 adults received no antifunga[ 
agent. In addition, 16 (15%)patients were treated 
with Low dosages of fluconazoLe. The overaLL mor- 
tality was 45%. MuLtivariate analysis indicated 
that prolonged hospital stay (P = 0.02; OR 2.95; CI 
1.14-7.62), central venous catheter-reLated infec- 
tion (P = 0.007; OR 3.40; CI 1.39-8.29) and inade- 
quate of antifunga[ treatment (P=0.03; OR 2.76; 
CI 1.09-6.99) were associated with candidemia- 
related death. The risk of death was similar in 
patients infected by C. albicans and those infected 
by non-aLbicans Candida spp. 
Conclusions: Candidemia is associated with a high 
mortality rate among criticaLLy iLL patients. In- 
creased awareness of risk factors and cLearLy de- 
fined infection control policies are needed to bet- 
ter address the problem of nosocomia[ Candida 
infections. 
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Introduction: Data on the use of caspofungin in 
combination with other systemic antifunga[ drugs 
for pediatric patients are scanty. 
Methods: A prospective study was performed from 
November 2002 to November 2005 to investigate 
the safety and efficacy of caspofungin-based com- 
bination therapy in children and adolescents. 
Results: Sixty-six patients were recruited with a 
median age at diagnosis of 11.3 years; most of 
them were affected by an underlying malignant 
disease. Twenty-one (32%) patients developed an 
invasive funga[ infection (IFI) after hematopoietic 
stem ceLL transplantation, 22 after primary diag- 
nosis, and 23 after relapse. Severe neutropenia 
was present in 52 (79%) patients. The mycoses 
were classified as possible in 17 (26%), probable 
in 20 (30%) and documented in 29 (44%) patients, 
respectively. A favorable response to antifunga[ 
therapy was obtained in 37 patients (56%) and the 
probability of 100-day survival was 72%. OveraLL, 
the combination therapy was weLL tolerated. After 
a median foLLow-up of 1.2 years, 31 patients were 
alive (47%). The probability of overaLL survival LOS) 
was significantly different for mycosis diagnosed 
after relapse, 20.9%, after HSCT, 32.4%, and after 
primary diagnosis, 48%, p 0.007. In a multivariate 
analysis, underlying disease status was the factor 
associated with favorable response, whilst factors 
associated with 100-day survival were the duration 
of therapy with caspofungin and the achievement 
of a favorable response; and those associated with 
OS were the occurrence of IFI after primary diag- 
nosis, use of surgery, and the achievement of a 
favorable response. 
Conclusion: This study showed that caspofungin- 
based combination antifunga[ therapy is an effica- 
cious therapeutic option for pediatric patients with 
invasive mycoses. These data need to be confirmed 
by prospective controLLed studies. 
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Background: RSV infection might be associated 
with high morbidity and mortality among immuno- 
compromised patients (pts). LittLe is known about 
the outcome of this infection in pts with Leukemia. 
Objectives: To evaluate the impact of antivi- 
ra[ therapy for RSV infection in patients with 
Leukemia. 
Materials & Methods: We reviewed the records of 
such pts seen at our institution between Oct 1999 
and Dec 2004 to determine the cLinicaL characteris- 
tics, risk factors, and outcome in Leukemia pts with 
RSV infection. 
